Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the design of MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place from May 29-31, 2020. The abstract, published in advance of the ASCO Annual Meeting, was made available at 5:00 PM ET today on the ASCO meeting website at https://meetinglibrary.asco.org/record/191686/abstract.
Details of the abstract presentation are as follows:
Hamilton et al. Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies
Poster Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
The poster presentation will be made available on the ASCO meeting website on Friday, May 29 at 8:00 AM ET. It will also be available online on the Company’s website at https://www.blackdiamondtherapeutics.com/technology/presentations-publications/.